期刊档案 · Medicine-Pharmacology (medical)
Therapeutic Advances in Drug Safety
ISSN 2042-0986 · eISSN 2042-0994 · SAGE · ENGLAND
Therapeutic Advances in Drug Safety 中科院 医学 3区(2025 年升级版),影响因子 3.17,完全开放获取,APC 约 2,800 美元,近 24 个月 98 篇文章投稿到接收中位 153 天,官网公布录用率 17.9%,2025 年发文 68 篇,SCIE、Scopus 收录。
研究范围
研究范围与定位
Therapeutic Advances in Drug Safety 由 SAGE 出版,属中科院医学大类(2025 升级版3区)。按 OpenAlex 近年发文统计,该刊主要发表 Pharmacovigilance and Adverse Drug Reactions、Pharmaceutical Practices and Patient Outcomes、Patient Safety and Medication Errors 等主题的论文,这 3 个主题约占 43.3%。(根据 OpenAlex 主题统计与中科院分区数据生成)
Therapeutic Advances in Drug Safety delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in drug safety, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of drug safety, including therapeutic drug monitoring, pharmacoepidemiology, adverse drug reactions, drug interactions, pharmacokinetics, pharmacovigilance, medication/prescribing errors, risk management, ethics and regulation.
来源:LetPub
研究方向(LetPub):Medicine-Pharmacology (medical)
主编 Arduino Mangoni出版商官网
编委会国家分布:未见中国大陆编委;主要国家 美国 23、英国 20、澳大利亚 14、意大利 6、加拿大 3(共 100 位编委标注了国家) 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计,占比为近似值
- Pharmacovigilance and Adverse Drug ReactionsPharmacology, Toxicology and Pharmaceutics19.5%
- Pharmaceutical Practices and Patient OutcomesMedicine17%
- Patient Safety and Medication ErrorsHealth Professions6.8%
- Medication Adherence and ComplianceMedicine5.6%
- Pharmaceutical studies and practicesMedicine5.5%
- Atrial Fibrillation Management and OutcomesMedicine3.6%
- Drug-Induced Adverse ReactionsMedicine3.2%
- Pharmaceutical Economics and PolicyEconomics, Econometrics and Finance3%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表( 2025年3月升级版)医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 3 区 |
Top 期刊:否综述期刊:否
《新锐期刊分区表》( 2026年3月发布)医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 2 区 |
Top 期刊:否综述期刊:未标注
期刊分区表( 2023年12月旧的升级版)医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 2 区 |
Top 期刊:否综述期刊:否
数据库收录
SCIEScopusDOAJLetPub
国际期刊预警名单:各版本均未列入LetPub
不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子
- 3.17LetPub ·
- 影响因子(出版商公布)
- 3.3出版商官网 ·
- 五年影响因子(出版商公布)
- 4.2出版商官网 ·
- CiteScore 2026-06
- 4.6LetPub ·
- SJR 2026-06
- 0.83LetPub ·
- SNIP 2026-06
- 1.31LetPub ·
- h-index
- 65OpenAlex ·
- i10-index
- 315OpenAlex ·
- 两年平均被引
- 3.93OpenAlex ·
- 自引率
- 0%LetPub ·
- Gold OA 文章占比
- 100%LetPub ·
发文规模
- 年文章数
- 64LetPub ·
逐年发文量 OpenAlex 统计 · 累计 614 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 59 | 59 | 36 |
| 2025 | 68 | 68 | 310 |
| 2024 | 51 | 51 | 353 |
| 2023 | 28 | 28 | 291 |
| 2022 | 35 | 35 | 676 |
| 2021 | 38 | 38 | 726 |
不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 PubMed 登记的稿件日期 · 至
153 天投稿到接收中位数 · P25–P75 119 天 – 194 天
- 接收到上线
- 中位数 32 天(99 篇)
- 投稿到上线
- 中位数 186 天
- 样本
- 98 篇有投稿与接收日期的文章(窗口内共 137 篇),最近一篇接收于
只统计最终被录用并发表的文章,不含被拒稿件的处理时间,因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度(社区反馈)
- 9 WeeksLetPub ·
- 录用率(出版商公布)
- 17.9%出版商官网 ·
- 投稿到首次决定
- 2 天出版商官网 ·
- 接收到发表
- 31 天出版商官网 ·
- 投稿到发表(期刊自报)
- 约 9 周DOAJ ·
- 评审方式
- 单盲同行评审DOAJ
社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
所有文章开放获取,通常向作者收取文章处理费(APC)。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | USD 2,800 | 有 | CC BY、CC BY-NC | |
| OpenAlex | USD 2,800 | — | — | |
| LetPub | USD 2,800 | 有 | — | |
| 出版商官网 | USD 3,200 / USD 5,000 | — | — |
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。
投稿要求
文章类型与投稿政策(官网)
接收的文章类型6 种
- original articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…未说明篇幅
- original research articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…未说明篇幅
- perspectiveView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…未说明篇幅
- reviewView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…未说明篇幅
- review articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…未说明篇幅
- systematic reviewView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…未说明篇幅
官网政策摘录作者资格、数据可用性、出版伦理、开放获取、同行评审、查重、预印本、试验注册 / 报告规范
- 作者资格 Author contributions
As part of our commitment to ensuring an ethical, transparent and fair peer review and publication process, this journal has adopted CRediT (Contributor Roles Taxonomy). CRediT is a high-level taxonomy, including 14 roles, which is used to describe each author’s individual contributions to the work. You will be asked to list the contribution of each author as part of the submission process. Please…
原文 ↗出版商官网 ·- 数据可用性 Data availability
The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…
原文 ↗出版商官网 ·- 出版伦理 Ethical considerations
Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…
原文 ↗出版商官网 ·- 开放获取 Publishing fees and open access
Therapeutic Advances in Drug Safety is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity. If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable to cover the cost of publishing, p…
原文 ↗出版商官网 ·- 同行评审 Peer review policy
The following summary describes the peer review process for this journal: Identity transparency: Single Anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk rejec…
原文 ↗出版商官网 ·- 查重 Plagiarism
The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.
原文 ↗出版商官网 ·- 预印本 Preprints
The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…
原文 ↗出版商官网 ·- 试验注册 / 报告规范 Clinical trial registration
The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
原文 ↗出版商官网 ·
摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。
基本信息
出版信息与官方入口
- 出版商
- SAGE
- 出版国家或地区
- ENGLAND
- 出版语言
- English
- ISSN
- 2042-0986
- 电子版 ISSN
- 2042-0994
- 官方链接
- 期刊主页 ↗OpenAlex
- 投稿系统 ↗出版商官网
- 作者指南 ↗LetPub
- Aims & Scope ↗LetPub
- 专刊 / 特刊征稿 ↗出版商官网
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗LetPub
- 编委会 ↗LetPub
- 查重政策 ↗DOAJ
常见问题
关于 Therapeutic Advances in Drug Safety 的常见问题
Therapeutic Advances in Drug Safety 是中科院几区期刊?
2025 年升级版分区表中,Therapeutic Advances in Drug Safety 为医学 3区,小类 药学 3 区。2026 年新锐版分区表中为医学 2区。不同版本与大小类分区不能混用。
Therapeutic Advances in Drug Safety 的影响因子是多少?
LetPub 汇总的最新公布影响因子为 3.17,CiteScore 为 4.6,h-index 为 65。
Therapeutic Advances in Drug Safety 的审稿周期多长?
按 2024年10月至2026年10月(近 24 个月)98 篇已发表文章登记的日期,投稿到接收的中位数为 153 天(四分位 119–194 天);投稿社区反馈的平均审稿速度为约 9 周;期刊官网公布的录用率为 17.9%。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。
Therapeutic Advances in Drug Safety 的编委会里有中国学者吗?
期刊官网编委会页面上标注了国家的 100 位编委中,没有中国大陆学者;人数最多的国家是 美国(23 位)、英国(20 位)、澳大利亚(14 位)。统计按编委会页面列出的机构国家计,仅供参考。
Therapeutic Advances in Drug Safety 被哪些数据库收录?
据 LetPub 与 DOAJ 记录,Therapeutic Advances in Drug Safety 被 SCIE、Scopus、DOAJ 收录。
Therapeutic Advances in Drug Safety 是开放获取期刊吗?版面费多少?
Therapeutic Advances in Drug Safety 为完全开放获取。APC 约 2,800 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex、DOAJ;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-25 归档)。最近更新:。